Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration

Toxicological Sciences

Volumn 86, Issue 2, 2005, Pages 248-257

  Kamat, Chandrashekhar D ^a   Green, Dixy E ^a   Curilla, Susan ^a   Warnke, Linda ^a   Hamilton, Joshua W ^b   Sturup, Stefan ^b   Clark, Callie ^a   Ihnat, Michael A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Arsenic; Hypoxia inducible factor; Tumorigenesis; Vascular endothelial growth factor

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ARSENIC TRIOXIDE; DRINKING WATER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SEMAXANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER TRANSPLANTATION; CELL ISOLATION; CONTROLLED STUDY; ENVIRONMENTAL PROTECTION; LONG TERM EXPOSURE; LUNG CARCINOGENESIS; LUNG METASTASIS; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ARSENIC; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MYOCARDIUM; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 26444449005     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfi190     Document Type: Article

References (42)

1. Adelman, D. M., Maltepe, E., and Simon, M. C. (1999). Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. [i#Genes Dev.#1i] [b#13,#1b] 2478-2483.
2. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., and Lawley, T. J. (1992). HMEC-1: Establishment of an immortalized human microvascular endothelial cell line. [i#J. Invest. Dermatol.#1i] [b#99,#1b] 683-690.
3. Andrew, A. S., Klei, L. R., and Barchowsky, A. (2001). Nickel requires hypoxia-inducible factor-1 alpha, not redox signaling, to induce plasminogen activator inhibitor-1. [i#Am. J. Physiol. Lung Cell. Mol. Physiol.#1i] [b#281,#1b] L607-L615.
4. Auguste, P., Lemiere, S., Larrieu-Lahargue, F., and Bikfalvi, A. (2005). Molecular mechanisms of tumor vascularization. [i#Crit. Rev. Oncol. Hematol.#1i] [b#54,#1b] 53-61.
5. Barchowsky, A., Klei, L. R., Dudek, E. J., Swartz, H. M., and James, P. E. (1999). Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. [i#Free Radic. Biol. Med.#1i] [b#27,#1b] 1405-1412.
6. Barkhordar, R. A., Berston, E. D., and Ramos, D. M. (1995). Cervical lymph node metastasis: Model for study of head/neck melanoma. [i#Eur. J. Cancer B Oral Oncol.#1i] [b#31B,#1b] 49-52.
7. Chun, Y. S., Kim, M. S., and Park, J. W. (2002). Oxygen-dependent and -independent regulation of HIF-1alpha. [i#J. Korean Med. Sci.#1i] [b#17,#1b] 581-588.
8. Chun, Y. S., Yeo, E. J., Choi, E., Teng, C. M., Bae, J. M., Kim, M. S., and Park, J. W. (2001). Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. [i#Biochem. Pharmacol.#1i] [b#61,#1b] 947-954.
9. Covello, K. L., and Simon, M. C. (2004). HIFs, hypoxia, and vascular development. [i#Curr. Top. Dev. Biol.#1i] [b#62,#1b] 37-54.
10. Cullen, B. R., and Malim, M. H. (1992). Secreted placental alkaline phosphatase as a eukaryotic reporter gene. [i#Methods Enzymol.#1i] [b#216,#1b] 362-368.
11. D'Amato, R. J., Lin, C. M., Flynn, E., Folkman, J., and Hamel, E. (1994). 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. [i#Proc. Natl. Acad. Sci. U.S.A.#1i] [b#91,#1b] 3964-3968.
12. Davison, K., Mann, K. K., and Miller, W. H., Jr. (2002). Arsenic trioxide: Mechanisms of action. [i#Semin. Hematol.#1i] [b#39,#1b] 3-7.
13. Duyndam, M. C., Hulscher, T. M., Fontijn, D., Pinedo, H. M., and Boven, E. (2001). Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. [i#J. Biol. Chem.#1i] [b#276,#1b] 48066-48076.
14. Duyndam, M. C., Hulsher, S. T., Van Der Wall, E., Pinedo, H. M., and Boven, E. (2003). Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite. [i#J. Biol. Chem.#1i] [b#278,#1b] 6885-6895.
15. Fidler, I. J., Gersten, D. M., and Budmen, M. B. (1976). Characterization [i#in vivo#1i] and [i#in vitro#1i] of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. [i#Cancer Res.#1i] [b#36,#1b] 3160-3165.
16. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., [i#et al.#1i] (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. [i#Cancer Res.#1i] [b#59,#1b] 99-106.
17. Gao, N., Shen, L., Zhang, Z., Leonard, S. S., He, H., Zhang, X. G., Shi, X., and Jiang, B. H. (2004). Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. [i#Mol. Cell. Biochem.#1i] [b#255,#1b] 33-45.
18. Hei, T. K., and Filipic, M. (2004). Role of oxidative damage in the genotoxicity of arsenic. [i#Free Radic. Biol. Med.#1i] [b#37,#1b] 574-581.
19. Jakob, W., Jentzsch, K. D., Mauersberger, B., and Heder, G. (1978). The chick embryo choriallantoic membrane as a bioassay for angiogenesis factors: Reactions induced by carrier materials. [i#Exp. Pathol. (Jena #1i] [b#15,#1b] 241-249.
20. Kao, Y. H., Yu, C. L., Chang, L. W., and Yu, H. S. (2003). Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis [i#in vitro. Chem. Res. Toxicol.#1i] [b#16,#1b] 460-468.
21. Kumagai, Y., and Pi, J. (2004). Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: Implication of endothelial dysfunction. [i#Toxicol. Appl. Pharmacol.#1i] [b#198,#1b] 450-457.
22. Liu, Y., Cox, S. R., Morita, T., and Kourembanas, S. (1995). Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. [i#Circ. Res.#1i] [b#77,#1b] 638-643.
23. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., and Giannakakou, P. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. [i#Cancer Cell#1i] [b#3,#1b] 363-375.
24. Marks, M. G., Shi, J., Fry, M. O., Xiao, Z., Trzyna, M., Pokala, V., Ihnat, M. A., and Li, P. K. (2002). Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. [i#Biol. Pharm. Bull.#1i] [b#25,#1b] 597-604.
25. McColl, B. K., Stacker, S. A., and Achen, M. G. (2004). Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. [i#APMIS#1i] [b#112,#1b] 463-480.
26. Michiels, C., Minet, E., Mottet, D., and Raes, M. (2002). Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. [i#Free Radic. Biol. Med.#1i] [b#33,#1b] 1231-1242.
27. Page, E. L., Robitaille, G. A., Pouyssegur, J., and Richard, D. E. (2002). Induction of Hypoxia-inducible Factor-1alpha by Transcriptional and Translational Mechanisms. [i#J. Biol. Chem.#1i] [b#277,#1b] 48403-48409.
28. Rahman, M. (2002). Arsenic and hypertension in Bangladesh. [i#Bull. World Health Organ.#1i] [b#80,#1b] 173.
29. Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L., Warrell, R. P., Jr., and Rafii, S. (2000). Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. [i#Blood#1i] [b#96,#1b] 1525-1530.
30. Rossman, T. G. (2003). Mechanism of arsenic carcinogenesis: An integrated approach. [i#Mutat Res.#1i] [b#533,#1b] 37-65.
31. Schmeisser, E., Goessler, W., Kienzl, N., and Francesconi, K. A. (2004). Volatile analytes formed from arsenosugars: Determination by HPLC-HG-ICPMS and implications for arsenic speciation analyses. [i#Anal. Chem.#1i] [b#76,#1b] 418-423.
32. Shi, H., Hudson, L. G., and Liu, K. J. (2004). Oxidative stress and apoptosis in metal ion-induced carcinogenesis. [i#Free Radic. Biol. Med.#1i] [b#37,#1b] 582-593.
33. Shi, J., Xiao, Z., Ihnat, M. A., Kamat, C., Pandit, B., Hu, Z., and Li, P. K. (2003). Structure-activity relationships studies of the anti-angiogenic activities of linomide. [i#Bioorg. Med. Chem. Lett.#1i] [b#13,#1b] 1187-1189.
34. Shinkaruk, S., Bayle, M., Lain, G., and Deleris, G. (2003). Vascular endothelial cell growth factor (VEGF). an emerging target for cancer chemotherapy. [i#Cur. Med. Chem. Anti-Canc. Agents#1i] [b#3,#1b] 95-117.
35. Soucy, N. V., Ihnat, M. A., Kamat, C. D., Hess, L., Post, M. J., Klei, L. R., Clark, C., and Barchowsky, A. (2003). Arsenic stimulates angiogenesis and tumorigenesis [i#in vivo. Toxicol. Sci.#1i] [b#76,#1b] 271-279.
36. Soucy, N. V., Klei, L. R., Mayka, D. D., and Barchowsky, A. (2004). Arsenic stimulates angiogenesis and tumorigenesis [i#in vivo. Chem. Res. Toxicol.#1i] [b#17,#1b] 555-563.
37. Steinmaus, C., Moore, L., Hopenhayn-Rich, C., Biggs, M. L., and Smith, A. H. (2000). Arsenic in drinking water and bladder cancer. [i#Cancer Invest.#1i] [b#18,#1b] 174-182.
38. Tchounwou, P. B., Patlolla, A. K., and Centeno, J. A. (2003). Carcinogenic and systemic health effects associated with arsenic exposure - a critical review. [i#Toxicol. Pathol.#1i] [b#31,#1b] 575-588.
39. Tseng, C. H. (2002). An overview on peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. [i#Angiology#1i] [b#53,#1b] 529-537.
40. Tseng, C. H., Tseng, C. P., Chiou, H. Y., Hsueh, Y. M., Chong, C. K., and Chen, C. J. (2002). Epidemiologic evidence of diabetogenic effect of arsenic. [i#Toxicol. Lett.#1i] [b#133,#1b] 69-76.
41. Wang, G. L., and Semenza, G. L. (1993). Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. [i#Blood#1i] [b#82,#1b] 3610-3615.
42. Yu, H. S., Lee, C. H., and Chen, G. S. (2002). Peripheral vascular diseases resulting from chronic arsenical poisoning. [i#J. Dermatol.#1i] [b#29,#1b] 123-130.